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Acute myeloid leukemia (AML) is a complex blood cancer that includes multiple genetic and 
epigenetic aberrations that contribute to disease biology. The molecular characterization of both 
adult and pediatric AML has found informative chromosomal rearrangements, DNA mutations, and 
gene expression changes that stratify patients into low, standard and high-risk prognostic categories. 
De-regulated gene expression and gene mutations are typically considered as two different 
categories of molecular alterations in leukemia. A recent study from the laboratory of Dr. Soheil 
Meschinchi (Clinical Research Division) "suggests that the interplay between gene over-expression 
and genotype may have biologic and prognostic importance," according to lead author Dr. Phoenix 
Ho. The researchers found that high expression of a mutated Wilms’ tumor suppressor 1 
(WT1) gene has different prognostic significance than high expression of WT1 with a single 
nucleotide polymorphism (SNP) in pediatric AML patients. 
Previous work by Dr. Ho and colleagues from the Children’s Oncology Group determined that 
inactivating mutations ofWT1 occur in 8% of pediatric AML patients. These mutations are associated 
with significantly worse survival outcomes (Ho et al., 2010). Similarly, WT1 mutations occur in 10% 
of adult AML patients. These DNA mutations are predicted to disrupt WT1 function as they occur in 
the zinc finger DNA binding regions of the WT1 protein, which functions as a transcription factor with 
both oncogenic and tumor suppressive roles. More commonly, 85% of pediatric AML patient blast 
cells have elevated WT1expression, both wild type and mutated. However, it has been unclear 
whether WT1 expression has independent prognostic significance. 
A previous study by Dr. Ho and colleagues (Ho et al., 2011) determined the presence of a 
synonymous SNP in the WT1 gene. SNPs occur throughout the genome and contribute to 
phenotypic diversity. Half of the SNPs identified result in a synonymous change in the DNA 
sequence that does not result in an amino acid change in the translated protein. SNP rs16754 is 
in WT1exon 7, where most inactivating mutations occur, and results in an A to G substitution in the 
third position of codon 352. This SNP occurs in around 29% of pediatric AML patients, and is more 
common in Asian and Hispanic patients than in white patients (P < 0.001). WT1 SNP rs16754 was 
associated with improved outcome in pediatric AML patients (hazard ratio 0.76; P = 0.031), as well 
as in adult AML patients. Notably, SNP rs16754 was associated with higher WT1 mRNA expression. 
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Taken together, these results indicate that this SNP has phenotypic consequences without altering 
WT1 protein sequence. 
The current study extends these findings with 225 patient diagnostic samples obtained from a 
contemporary Children’s Oncology Group clinical trial with uniformly treated pediatric AML patients. 
Importantly, when both SNP-positive and SNP-negative samples were analyzed together, overall 
survival was similar for high and low WT1 expression levels. WT1 expression varied widely, but was 
divided into four quartiles of increasing expression. When only SNP-negative patients were 
analyzed, those with the highest WT1 expression had the poorest overall survival by univariate 
analysis (51% quartile 4 vs. 72% for quartiles 1-3, P = 0.006, see figure). No differences were 
significant in the SNP-positive patients even with high WT1 expression. When other risk factors were 
included as covariates, high WT1 expression did not retain significance as an independent 
prognostic marker. Ho et al. conclude that while measuring WT1 expression does not appear to 
have clinical utility for pediatric AML patients, assessing WT1 mutations and SNPs aid in prognosis. 
 
The Meshinchi laboratory is currently pursuing exactly how this synonymous SNP contributes to both 
higher WT1 expression and favorable survival outcomes. Synonymous SNPs may affect microRNA 
binding, protein folding, mRNA stability, splicing or expression.  "We're investigating whether this 
SNP is inherited as part of a haplotype including SNPs in the promoter region of WT1 which may 
regulate the gene's expression," according to Dr. Ho.  Furthermore, this SNP may represent a 
genetic marker for an uncharacterized molecular change that influences response to chemotherapy. 
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Image provided by Phoenix Ho 
Survival outcomes for pediatric AML patients wild type for WT1 
SNP rs16754, as estimated by the Kaplan-Meier method. SNP 
negative patients with diagnostic WT1 expression in the highest 
quartile had significantly decreased overall survival. 
 
